21 Dec Dr. Pradeep Chaluvally-Raghavan awarded DOD grant
Pradeep Chaluvally-Raghavan, PhD has been awarded a Department of Defense (DOD) grant on Targeting miR551b to prevent Tumor formation and Metastasis of Triple Negative Breast Cancer.
The overarching goal of this grant is to advance the current strategies that prevent tumor progression to more effective and less toxic than those that currently exist and to prevent the metastasis. In this study, we are characterizing the role of a newly identified microRNA for its oncogenic actions and inhibiting miR551b to prevent the growth and metastasis of breast cancer cells. Our studies identified that miR551b acts as a central mediator of signaling addiction in breast cancer through the activation of NOTCH3 and STAT3 for tumor metastasis. To inhibit miR551b, we are using RNA interference (RNAi) approaches employing anti-microRNAs specifically bind on miR551b and inhibit its expression. We are expecting that our studies will advance the field of breast cancer research by providing novel targets for therapy and prevention of metastasis.
Dr. Pradeep Chaluvally-Raghavan received PhD degree in 2006 from the University of Calicut, India where he focused on the role NF-kappa B activation and pro-inflammatory cytokine genes in melanoma models. After completion of graduate school, he moved to the laboratory of Dr. Yosef Yarden at the Weizmann Institute of Sciences, Israel for postdoctoral research. In Dr. Yarden’s laboratory, he studied the role of epidermal growth factor receptor (EGFR) family members in breast cancer progression. In 2016, he was recruited as a tenure track Assistant Professor to the Department of Obstetrics and Gynecology at the Medical College of Wisconsin. In the current position Dr. Chaluvally continues his post-doctoral work initiated in the Mills lab, and extends this research into other areas of non-coding RNA biology. Specifically, he is studying the role of non-coding RNA in mediating transcriptional and post-transcriptional regulation of gene expression. Over the last 6 years, he has made major scientific contributions to our understanding of the role of non-coding RNA aberrations as part of the CNVs in cancer.